Simotinib

Drug Profile

Simotinib

Alternative Names: AL-6802; SIM-6802; Simotinib hydrochloride; Ximotini

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Advenchen Laboratories
  • Developer Advenchen Laboratories; Simcere Pharmaceutical Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 15 Apr 2016 Chemical structure information added
  • 12 Apr 2016 Phase I development is ongoing in China
  • 01 Dec 2012 Phase-I clinical trials in Non-small cell lung cancer in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top